In endoscopic ultrasound, proper coding is a key factor as documentation directly influences reimbursement and compliance. CPT 43237 is usually utilized when a diagnostic EGD is coupled with a limited EUS examination of specific areas of the upper GI tract and adjacent structures. Since the choice of the code is determined by the level of the ultrasound examination, any small deficiencies in documentation can result in denials or undercoding.
It thus becomes important to effectively document the examined areas, clinical purpose and procedural specifications to prevent misalignment with advanced EUS or biopsy-dependent codes.
CPT 43237 – Description
Official Definition: “Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination limited to the esophagus, stomach, or duodenum, and adjacent structures.”
This code is used to refer to an upper GI endoscopy with endoscopic ultrasound imaging. The physician will insert a special echoendoscope via the mouth to examine the upper GI tract, and then to measure the deeper layers of the walls, periluminal structures and lymph nodes located near the mouth with the inbuilt ultrasound transducer.
CPT 43237 is restricted to EUS of esophagus, stomach, duodenum and surrounding structures. Assessment of the pancreas, bile ducts, or mediastinum outside of neighboring structures, or EUS with fine-needle aspiration is covered under different codes (43238, 43242). The code includes the visual EGD as well as the ultrasound imaging during one session.
When to Use CPT 43237
CPT 43237 should be used when the provider conducts a diagnostic EGD and endoscopic ultrasound of the upper GI tract without tissue sampling. It is most commonly used in staging and wall-layer assessment and characterization of submucosal lesions. .
Typical clinical signs are:
- Staging of esophageal or gastric cancer (T-stage and local nodal assessment).
- Evaluation of submucosal tumors such as GIST, leiomyoma, or lipoma.
- Assessment of wall thickening or suspected intramural lesions seen on CT or MRI.
- Evaluation of esophageal varices or portal hypertension imaging.
- Characterization of subepithelial abnormalities or thickened gastric folds.
Do not report 43237 for:
- EUS with fine-needle aspiration or biopsy (use 43238 or 43242).
- EUS including the pancreas, bile duct, or liver (use 43259 or 43242).
- Diagnostic EGD without ultrasound (use 43235).
- Esophageal EUS only, without entering the stomach or duodenum (use 43231).
- EUS-guided therapeutic interventions such as pseudocyst drainage (use 43240).
Reimbursement and Billing Insights For CPT Code 43237
CPT 43237 is paid more than diagnostic EGD because of the complexity of the added imaging, and less than full EUS procedures.
- Payment varies by facility vs non-facility setting
- Moderate sedation may be billed separately (payer-dependent)
- Higher reimbursement compared to standard EGD
- Requires strong documentation for medical necessity
Key billing focus:
Use of correct code selection depending on the extent of EUS and not on the procedure done.
Applicable Modifiers For CPT Code 43237
Modifiers can serve to explain billing situations:
- Modifier 22 – Increased procedural services when EUS was significantly more complex than usual; supporting documentation required.
- Modifier 52 – Reduced services when the planned EUS extent could not be completed due to anatomy or patient tolerance.
- Modifier 53 – Discontinued procedure due to patient-related complications before completion.
- Modifier 59 or XS – Rarely required; only when distinct-site or distinct-procedure documentation justifies overriding an NCCI edit with another endoscopy code.
- Modifier 74 – Discontinued outpatient procedure after anesthesia administration (ASC/hospital outpatient use).
- Modifier 51 – Multiple procedures when 43237 is performed with another unrelated procedure on the same day.
Component modifiers (26/TC) do not apply to 43237 as it is a global surgical code that includes both the endoscopic and ultrasound work. Always confirm payer-specific modifier acceptance before submission.
Documentation Requirements For CPT Code 43237
Accurate documentation will contribute to the medical necessity and safeguard against refusals. Procedure notes must contain:
- Clinical indication and ICD-10 diagnosis in favor of the LCD.
- Pre-procedure agreement, anesthesia plan and vital signs.
- Scope type (echoendoscope), route (transoral), and extent reached.
- Visual findings in the esophagus, stomach, and duodenum.
- EUS findings including wall-layer evaluation, lesion size and location, echogenicity, and assessment of adjacent structures and lymph nodes.
- Confirmation that no FNA or biopsy was performed (to justify 43237 versus 43238/43242).
- Stored ultrasound images and interpretation.
- Sedation time and medications, with independent observer when required for Medicare.
- Post-procedure status, complications, and recovery notes.
- Signed report of procedure by performing gastroenterologist.
Example Scenarios For CPT Code 43237
- Scenario 1: A gastroenterologist is doing an EGD with EUS to stage a known esophageal adenocarcinoma, evaluating the tumor depth and local lymph nodes, but no FNA. → Report CPT 43237.
- Scenario 2: EUS performed to characterize a gastric submucosal mass; no tissue sampling done. → Report CPT 43237.
- Scenario 3: EUS with fine-needle aspiration of a periesophageal lymph node. → Do not report 43237; use 43238 (EUS with FNA of the upper GI tract).
- Scenario 4: EUS examination extending to the pancreas for evaluation of a suspicious mass. → Do not report 43237; use 43259 (EUS including pancreas and adjacent structures).
Reduce EUS Denials to <1% with BillingFreedom’s Advanced GI Billing Expertise
Endoscopic ultrasound billing involves proper selection of codes, proper documentation of areas explored and proper compliance with bundling regulations, particularly when differentiating between limited EUS and full EUS or FNA based procedures. Any little documentation error or mismatch of code pairs may result in denials or downcoding.
At BillingFreedom, our gastroenterology medical billing workflows are built to minimize these risks through structured validation and real-time compliance checks.
- <1% denial rate across GI endoscopy claims
- 98%+ clean claim accuracy
- 95%+ first-pass acceptance rate
- 20–30% measurable revenue improvement
Our team ensures:
- Correct differentiation between limited and full EUS exams
- Proper handling of EUS with FNA/biopsy bundling rules
- Accurate sedation coding and modifier sequencing
- Pre-authorization and LCD-based medical necessity validation
BillingFreedom assists in maintaining claims in compliance, minimizes revenue leakage, and aids in maintaining a consistent flow of reimbursement of gastroenterology practices with constant monitoring of CMS updates, payer policies, and coding guidelines.
For more details about our exceptional Gastroenterology medical billing services, please don't hesitate to contact us via email at info@billingfreedom.com or call us at +1 (855) 415-3472.
Your financial tranquility is our priority!
Related ICD-10-CM Codes
ICD-10-CM Codes
C15.3 - Malignant neoplasm of upper third of esophagus
C15.4 - Malignant neoplasm of middle third of esophagus
C15.5 - Malignant neoplasm of lower third of esophagus
C15.8 - Malignant neoplasm of overlapping sites of esophagus
C73 - Malignant neoplasm of thyroid gland
C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified
C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.80 - Secondary malignant neoplasm of unspecified digestive organ
C78.89 - Secondary malignant neoplasm of other digestive organs
C79.89 - Secondary malignant neoplasm of other specified sites
C79.9 - Secondary malignant neoplasm of unspecified site
C7A.098 - Malignant carcinoid tumors of other sites
D00.1 - Carcinoma in situ of esophagus
D13.99 - Benign neoplasm of ill-defined sites within the digestive system
D37.8 - Neoplasm of uncertain behavior of other specified digestive organs
D37.9 - Neoplasm of uncertain behavior of digestive organ, unspecified
D3A.098 - Benign carcinoid tumors of other sites
F45.8 - Other somatoform disorders
F50.010 - Anorexia nervosa, restricting type, mild
F50.011 - Anorexia nervosa, restricting type, moderate
F50.012 - Anorexia nervosa, restricting type, severe
F50.013 - Anorexia nervosa, restricting type, extreme
F50.014 - Anorexia nervosa, restricting type, in remission
F50.019 - Anorexia nervosa, restricting type, unspecified
F50.020 - Anorexia nervosa, binge eating/purging type, mild
F50.021 - Anorexia nervosa, binge eating/purging type, moderate
F50.022 - Anorexia nervosa, binge eating/purging type, severe
F50.023 - Anorexia nervosa, binge eating/purging type, extreme
F50.024 - Anorexia nervosa, binge eating/purging type, in remission
F50.029 - Anorexia nervosa, binge eating/purging type, unspecified
F50.20 - Bulimia nervosa, unspecified
F50.21 - Bulimia nervosa, mild
F50.22 - Bulimia nervosa, moderate
F50.23 - Bulimia nervosa, severe
F50.24 - Bulimia nervosa, extreme
F50.25 - Bulimia nervosa, in remission
F50.810 - Binge eating disorder, mild
F50.811 - Binge eating disorder, moderate
F50.812 - Binge eating disorder, severe
F50.813 - Binge eating disorder, extreme
F50.814 - Binge eating disorder, in remission
F50.819 - Binge eating disorder, unspecified
F50.83 - Pica in adults
F50.84 - Rumination disorder in adults
F98.21 - Rumination disorder of infancy and childhood
G52.2 - Disorders of vagus nerve
K20.0 - Eosinophilic esophagitis
K21.9 - Gastro-esophageal reflux disease without esophagitis
K22.11 - Ulcer of esophagus with bleeding
K22.2 - Esophageal obstruction
K22.3 - Perforation of esophagus
K22.5 - Diverticulum of esophagus, acquired
K22.6 - Gastro-esophageal laceration-hemorrhage syndrome
K22.70 - Barrett's esophagus without dysplasia
K22.710 - Barrett's esophagus with low grade dysplasia
K22.711 - Barrett's esophagus with high grade dysplasia
K22.719 - Barrett's esophagus with dysplasia, unspecified
K22.89 - Other specified disease of esophagus
K22.9 - Disease of esophagus, unspecified
K23 - Disorders of esophagus in diseases classified elsewhere
K44.0 - Diaphragmatic hernia with obstruction, without gangrene
K92.1 - Melena
K92.2 - Gastrointestinal hemorrhage, unspecified
Q39.5 - Congenital dilatation of esophagus
Q39.6 - Congenital diverticulum of esophagus
Q39.8 - Other congenital malformations of esophagus
Q39.9 - Congenital malformation of esophagus, unspecified
Q85.82 - Other Cowden syndrome
Q85.83 - Von Hippel-Lindau syndrome
Q85.89 - Other phakomatoses, not elsewhere classified
R07.0 - Pain in throat
R10.20 - Pelvic and perineal pain unspecified side
R10.21 - Pelvic and perineal pain right side
R10.22 - Pelvic and perineal pain left side
R10.23 - Pelvic and perineal pain bilateral
R10.24 - Suprapubic pain
R10.85 - Abdominal pain of multiple sites
R11.16 - Cannabis hyperemesis syndrome
R12 - Heartburn
R13.11 - Dysphagia, oral phase
R13.13 - Dysphagia, pharyngeal phase
R13.14 - Dysphagia, pharyngoesophageal phase
R13.19 - Other dysphagia
R93.3 - Abnormal findings on diagnostic imaging of other parts of digestive tract
T18.3XXD - Foreign body in small intestine, subsequent encounter
T18.3XXS - Foreign body in small intestine, sequela
T18.8XXD - Foreign body in other parts of alimentary tract, subsequent encounter
T18.9XXD - Foreign body of alimentary tract, part unspecified, subsequent encounter
T18.9XXS - Foreign body of alimentary tract, part unspecified, sequela
T54.1X1D - Toxic effect of other corrosive organic compounds, accidental (unintentional), subsequent encounter
T54.1X1S - Toxic effect of other corrosive organic compounds, accidental (unintentional), sequela
T54.1X2D - Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter
T54.1X2S - Toxic effect of other corrosive organic compounds, intentional self-harm, sequela
T54.1X3D - Toxic effect of other corrosive organic compounds, assault, subsequent encounter
T54.1X3S - Toxic effect of other corrosive organic compounds, assault, sequela
T54.1X4D - Toxic effect of other corrosive organic compounds, undetermined, subsequent encounter
T54.1X4S - Toxic effect of other corrosive organic compounds, undetermined, sequela
T54.2X1D - Toxic effect of corrosive acids and acid-like substances, accidental (unintentional), subsequent encounter
T54.2X1S - Toxic effect of corrosive acids and acid-like substances, accidental (unintentional), sequela
T54.2X2D - Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter
T54.2X2S - Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela
T54.2X3D - Toxic effect of corrosive acids and acid-like substances, assault, subsequent encounter
T54.2X3S - Toxic effect of corrosive acids and acid-like substances, assault, sequela
T54.2X4D - Toxic effect of corrosive acids and acid-like substances, undetermined, subsequent encounter
T54.2X4S - Toxic effect of corrosive acids and acid-like substances, undetermined, sequela
T54.3X1D - Toxic effect of corrosive alkalis and alkali-like substances, accidental (unintentional), subsequent encounter
T54.3X1S - Toxic effect of corrosive alkalis and alkali-like substances, accidental (unintentional), sequela
T54.3X2D - Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter
T54.3X2S - Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela
T54.3X3D - Toxic effect of corrosive alkalis and alkali-like substances, assault, subsequent encounter
T54.3X3S - Toxic effect of corrosive alkalis and alkali-like substances, assault, sequela
T54.3X4D - Toxic effect of corrosive alkalis and alkali-like substances, undetermined, subsequent encounter
T54.3X4S - Toxic effect of corrosive alkalis and alkali-like substances, undetermined, sequela
T54.91XD - Toxic effect of unspecified corrosive substance, accidental (unintentional), subsequent encounter
T54.91XS - Toxic effect of unspecified corrosive substance, accidental (unintentional), sequela
T54.92XD - Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter
T54.92XS - Toxic effect of unspecified corrosive substance, intentional self-harm, sequela
T54.93XD - Toxic effect of unspecified corrosive substance, assault, subsequent encounter
T54.93XS - Toxic effect of unspecified corrosive substance, assault, sequela
T54.94XD - Toxic effect of unspecified corrosive substance, undetermined, subsequent encounter
T54.94XS - Toxic effect of unspecified corrosive substance, undetermined, sequela
T57.1X1D - Toxic effect of phosphorus and its compounds, accidental (unintentional), subsequent encounter
T57.1X1S - Toxic effect of phosphorus and its compounds, accidental (unintentional), sequela
T57.1X2D - Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter
T57.1X2S - Toxic effect of phosphorus and its compounds, intentional self-harm, sequela
T57.1X3D - Toxic effect of phosphorus and its compounds, assault, subsequent encounter
T57.1X3S - Toxic effect of phosphorus and its compounds, assault, sequela
T57.1X4D - Toxic effect of phosphorus and its compounds, undetermined, subsequent encounter
T57.1X4S - Toxic effect of phosphorus and its compounds, undetermined, sequela
T65.5X1D - Toxic effect of nitroglycerin and other nitric acids and esters, accidental (unintentional), subsequent encounter
T65.5X1S - Toxic effect of nitroglycerin and other nitric acids and esters, accidental (unintentional), sequela
T65.5X2D - Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter
T65.5X2S - Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela
T65.5X3D - Toxic effect of nitroglycerin and other nitric acids and esters, assault, subsequent encounter
T65.5X3S - Toxic effect of nitroglycerin and other nitric acids and esters, assault, sequela
T65.5X4D - Toxic effect of nitroglycerin and other nitric acids and esters, undetermined, subsequent encounter
T65.5X4S - Toxic effect of nitroglycerin and other nitric acids and esters, undetermined, sequela
Z15.068 - Genetic susceptibility to other malignant neoplasm of digestive system
Z86.003 - Personal history of in-situ neoplasm of oral cavity, esophagus and stomach
Z86.004 - Personal history of in-situ neoplasm of other and unspecified digestive organs
Related CPT Codes
CPT Codes
43235 - Complete Billing & Coding Guide for Diagnostic Esophagogastroduodenoscopy (EGD)
43236 - Complete Billing & Coding Guide for EGD with Directed Submucosal Injection
43238 - Complete Billing & Coding Guide for EGD with EUS-Guided Fine Needle Aspiration
43239 - Complete Billing & Coding Guide for EGD with Biopsy
43244 - Complete Billing & Coding Guide for EGD with Band Ligation of Esophageal and Gastric Varices
43245 - Complete Billing & Coding Guide for EGD with Dilation of Gastric or Duodenal Strictures
43248 - Complete Billing & Coding Guide for EGD with Guidewire-Assisted Esophageal Dilation
43249 - Complete Billing & Coding Guide for EGD With Esophageal Balloon Dilation
43251 - Complete Billing & Coding Guide for EGD With Snare Removal of Lesions